Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications
Journal of Neurology · 2024
DOI: 10.1007/s00415-024-12362-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurology, 2024. Verfasst von Antonio Luca Spiezia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University …. Hauptthemen laut MEDLINE: Multiple Sclerosis, Chronic Progressive, Azetidines, Lymphocyte Subsets, Benzyl Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Napoli Federico II.
Abstract (Originalsprache)
Background
Circulating immune cells play a pathogenic role in multiple sclerosis (MS). However, the role of specific lymphocyte subpopulations is not unveiled yet, especially in progressive stages. We aimed to investigate lymphocyte changes during siponimod treatment in active secondary progressive MS (aSPMS) and their associations with clinical outcomes.
Methods
We enrolled 46 aSPMS patients starting on siponimod treatment with at least 6 months of follow-up and two visits within the scheduled timeframes and 14 sex- and age-matched healthy controls (HCs). Clinical and laboratory data were collected retrospectively at baseline, 3rd, 6th, 12th, and 24th month for MS patients, and at baseline for HCs.
Results
At baseline SPMS patients presented with increased naïve regulatory T lymphocytes ( p = 0.02) vs. HCs. Over time, SPMS patients showed decreased T CD4+ (coeff. range = −24/−17, 95% CI range = −31.60 to −10.40), B lymphocyte (coeff. range = −3.77/−2.54, 95% CI range = −6.02 to −0.35), memory regulatory B cells (coeff. range = −0.78/−0.57, 95% CI range = −1.24 to −0.17) and CD4/CD8 ratio (coeff. range = −4.44/−0.67, 95% CI range = −1.61 to −0.17) from month 3 thereafter vs. baseline, and reduced CD3+CD20+ lymphocytes from month 12 thereafter (coeff. range = −0.32/−0.24, 95% CI range = −0.59 to −0.03). Patients not experiencing disability progression while on siponimod treatment showed B lymphocyte reduction from month 3 (coeff. range = −4.23/−2.32, 95% CI range = −7.53 to −0.15) and CD3+CD20+ lymphocyte reduction from month 12 (coeff. range = −0.32/−0.24, 95% CI range = −0.59 to −0.03) vs. patients experiencing progression.
Conclusions
Patients treated with siponimod showed a T and B lymphocyte reduction, especially CD4+, CD3+CD20+ and naïve regulatory T cells and memory regulatory B cells. Disability progression while on siponimod treatment was associated with a less pronounced effect on B and CD3+CD20+ lymphocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Via Sergio Pansini 5, 80131, Naples, Italy.
- Clinical and Experimental Cytometry Unit, Centre for Advanced Biotechnology Franco Salvatore, CEINGE, Naples, Italy.
- Department of Human Neurosciences, Sapienza University, Rome, Italy.
- Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Naples, Italy.
- Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Via Sergio Pansini 5, 80131, Naples, Italy. carotenuto.anto…
Förderung
- Università degli Studi di Napoli Federico II
Zitieren
APA
Spiezia, A. L., Scalia, G., Petracca, M., Caliendo, D., Moccia, M., Fiore, A., Cerbone, V., Lanzillo, R., Brescia Morra, V., & Carotenuto, A. (2024). Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications. Journal of Neurology. https://doi.org/10.1007/s00415-024-12362-9
Vancouver
Spiezia AL, Scalia G, Petracca M, Caliendo D, Moccia M, Fiore A, et al. Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications. Journal of Neurology. 2024. doi:10.1007/s00415-024-12362-9
BibTeX
@article{Spiezia2024,
author = {Spiezia, Antonio Luca and Scalia, Giulia and Petracca, Maria and Caliendo, Daniele and Moccia, Marcello and Fiore, Antonia and Cerbone, Vincenza and Lanzillo, Roberta and Brescia Morra, Vincenzo and Carotenuto, Antonio},
title = {Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications},
journal = {Journal of Neurology},
year = {2024},
doi = {10.1007/s00415-024-12362-9}
}
EUVIMED